Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies
Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing
round. This financing is the largest ever private funding round for a dialysis device company.
“We are excited to help contribute to and support Quanta’s commitment to modernise and overhaul
the outdated treatment paradigm in hemodialysis treatment, which has not seen substantial
innovation for several decades” said Roger Gunnarsson, SMA’s Managing Partner.
“The SC+ system is an innovative cartridge-based invention that is compact, simple, and powerful. It
is set to fundamentally change the way that dialysis care is provided, in every setting from specialized
dialysis centres to acute care hospitals, and increasingly moving into the home.
With this growth
capital, Quanta has the resources to drive improved patient outcomes and convenience while
accelerating market penetration and scale.”
The funding will allow the UK-company Quanta to scale up global operations with a focus on the
United States, where SC+ received 510(k) clearance from the FDA in December for use in acute and
chronic care facilities. The company is investing in significant infrastructure to scale up
manufacturing, sales and customer service functions to support use in currently approved care
settings within the United States, while also preparing to launch a study to support its future FDA
clearance for in-home use within the United States.
“We are delighted to attract such a strong syndicate of investors, which represents a clear vote of
confidence in our innovative approach to dialysis treatment,” said John E. Milad, CEO of Quanta.
“Everybody knows that dialysis care must improve. For this to happen, providers and physicians need
products that allow greater flexibility to bring dialysis directly to the patient, while simplifying
complexity and reducing the overall cost of care.
Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this market.”
The financing round was led by Glenview Capital and co-led by Novo Holdings, with support from a
broad group of other top-tier investors, including BlackRock, Eldridge, Sands Capital, Millennium,
Monashee Investment Management LLC., Puhua Capital, Segulah Medical Acceleration and Ancora,
alongside Orlando Health, an integrated delivery network. Existing shareholders also participated in
the round, including Wellington Partners, btov, Seroba Life Sciences and The Grands.
“Innovation in kidney dialysis has been stagnant for too long – but the demand from patients,
doctors, health care providers and payors for new, better and more flexible solutions is impossible to
ignore,” said Johan de Ruiter, Chairman of Quanta.
“We are excited to scale up our operations, enabling us to provide access to this critical new
technology that will save lives, improve patients’ quality of life and lower healthcare costs.”